SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) , the adenosine analogue 9-(Tetrahydro-2-furyl)adenine, inhibited adenylate cyclase activity of crude membrane preparations from catfish (Ictalurus melas) and rat isolated hepatocytes in a non-competitive manner.

SQ22536 (250 μMol/L) 减弱了腺苷对ADP诱导的血小板聚集的抑制效应，将其从8±5%降至57±5%（p<0.001）。SQ22536同样减弱了腺苷使血小板内cAMP水平上升的效应，从29±2 pmol/108血小板降至9±1 pmol/108血小板（p<0.05）。它对肌苷（1至4 mmol/L）的血小板抗聚集活性及ADP诱导的血小板聚集[4]没有影响。

SQ22536消除了利拉鲁肽对KK/Ta-Akita小鼠肾脏保护作用。在与SQ22536联合处理的KK/Ta-Akita小鼠中，利拉鲁肽改善肾小球组织病理损伤的作用被消除。经SQ22536处理后，肾脏cAMP水平不增加。总之，SQ22536这一腺苷酸环化酶抑制剂抑制了利拉鲁肽治疗肾病的有益作用[5]。

HMC-1 cells and hCBMCs are plated in 48-well plates and serum-starved overnight. The next day, cells are preincubated with SQ22536 at the indicated concentrations for 30 min before stimulation with CRH (100 nM for HMC-1 or 1 μM for hCBMC) for 3 min in the presence or absence of SQ22536 in serum-free culture media. Cell lysates are then prepared and assayed for protein kinase A activity using ELISA.(Only for Reference)